A Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of long-Acting Injectable Formulation of Vanoxerine (Vanoxerine Consta 394.2 mg) for Treatment of Amphetamine-Type Stimulant (ATS) Dependence.“

Objective: To determine efficacy and tolerability of a long-acting intramuscular formulation of Vanoxerine (Vanoxerine Consta 394.2 mg) for treatment of Amphetamine-Type Stimulant (ATS)  dependent patients.
Design, Setting, And Participants: A 12 weeks, A multicenter, randomized, placebo-controlled trial  conducted between November 2022--- December 2023, at 16 Hospital-based drug clinics, in the 15 countries. Participants were 18 years or older, had Diagnostic and Statistical Manual of Mental Disorders-5 Stimulant Use Disorder Amphetamine-Type (ATS). Of the 4000 individuals screened, 3300  (82.5%) adults were randomized, 1650 participants to receive injections of Long-acting depot formulations of Vanoxerine (Vanoxerine Consta 394.2 mg) given intramuscularly once in 12 weeks and 1650  participants to receive Placebo injections, given intramuscularly once in 12 weeks.

Article file ID not found.

The authors declare no conflict of interest.

Not applicable

The datasets used in this study are openly available at [repository link] and the source code is available on GitHub at [GitHub link].

This work did not receive any external funding.